A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-22 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
=== Transformation in the environment === The silver nanoparticles that pass through wastewater treatment plants undergo transformations in the environment through changes in aggregation state, oxidation state, precipitation of secondary phases, or sorption of organic species. These transformations can result in the formation of colloidal solutions. Each of these new species potentially have toxic effects which have yet to be fully examined. Most silver nanoparticles in products have an organic shell structure around a core of Ag0. This shell is often created with carboxylic acids functional groups, usually using citrate, leading to stabilization through adsorption or covalent attachment of organic compounds. In seawater, glutathione reacts with citrate to form a thioester via esterification.
In nuclear engineering, fissile material is material that can undergo nuclear fission when struck by a neutron of low energy. A self-sustaining thermal chain reaction can only be achieved with fissile material. The predominant neutron energy in a system may be typified by either slow neutrons (i.e., a thermal system) or fast neutrons. Fissile material can be used to fuel thermal-neutron reactors, fast-neutron reactors and nuclear explosives.
Estradiol is available as a transdermal gel in the form of gel dispensers and gel packets. Major estradiol gel dispenser products include EstroGel and Elestrin while major estradiol gel packet products include DiviGel and Sandrena. Estradiol gels are administered daily. When estradiol is administered as a hydroalcoholic gel, it dries within 2 to 5 minutes following application to the skin. A single application of a transdermal estradiol gel results in a sustained increase in estradiol levels for at least 24 hours. The apparent elimination half-life of estradiol with transdermal estradiol gel is 36 hours. Once daily application of 1.25 g topical gel containing 0.75 mg estradiol (brand name EstroGel) for 2 weeks was found to produce mean peak estradiol and estrone levels of 46.4 pg/mL and 64.2 pg/mL, respectively. The time-averaged levels of circulating estradiol and estrone with this formulation over the 24-hour dose interval were 28.3 pg/mL and 48.6 pg/mL, respectively. Levels of estradiol and estrone are stable and change relatively little over the course of the 24 hours following an application, indicating a long duration of action of this route. Steady-state levels of estradiol are achieved after 3 days of application. A higher dosage of estradiol gel containing 1.5 mg estradiol per daily application has been found to produce mean estradiol levels of 40 to 100 pg/mL and estrone levels of 90 pg/mL, while 3 mg per day has been found to result in respective mean estradiol and estrone levels of 60 to 140 pg/mL and 45 to 155 pg/mL.
The involvement of the king's son-in-law Iñaki Urdangarín in the corruption scandal known as the Nóos affair caused enormous damage to the image of the monarchy, as polls immediately reflected. The first official reaction of the Casa del Rey came on December 12, 2011, when it was decided to remove Urdangarín from official acts due to his "non-exemplary" behavior. In the Christmas Message the king spoke of "justice being equal for all". Four days later, Urdangarín was charged and between Saturday 25 and Sunday February 26, 2012, he had to testify before the judge in Palma de Mallorca. Another hard blow to the prestige of the monarchy came two months later, when on April 14, 2012, it was learned that King Juan Carlos had broken his hip on an elephant hunt in Botswana and that he had been rushed to Madrid for surgery. The news sparked a huge controversy that forced the king to apologize when he left the clinic. "I am very sorry. I made a mistake and it won't happen again," he said. On November 21, 2013, the king underwent another hip operation. It was the third surgery in less than a year, and the ninth in the last five. At the first official act in which he intervened, the celebration of Pascua Militar on January 6, 2014, he appeared tired and unwell. Just one day later, the judge of the Nóos affair, José Castro Aragón, charged the infanta Cristina de Borbón for the second time – the first had been dismissed the previous year by the Audiencia de Palma – for money laundering and tax crimes.
Sources: en.wikipedia.org
=== No development reported === Bupropion (Wellbutrin) – norepinephrine–dopamine reuptake inhibitor (NDRI) and nicotinic acetylcholine receptor negative allosteric modulator EX-597 (KDS-4103; ORG-231295; URB-597) – fatty acid amide hydrolase (FAAH) inhibitor Guanfacine extended-release (Connexyn; Intuniv; Intuniv XR; S-877503; SHP-503; SPD-503) – α2-adrenergic receptor agonist
=== Alcohol === Alcohol has biological, mental, and social effects which influence the consequences of using alcohol for pain. Moderate use of alcohol can lessen certain types of pain in certain circumstances. The majority of its analgesic effects come from antagonizing NMDA receptors, similarly to ketamine, thus decreasing the activity of the primary excitatory (signal boosting) neurotransmitter, glutamate. It also functions as an analgesic to a lesser degree by increasing the activity of the primary inhibitory (signal reducing) neurotransmitter, GABA. Attempting to use alcohol to treat pain has also been observed to lead to negative outcomes including excessive drinking and alcohol use disorder.
== External links == Media related to Counterfeit medications at Wikimedia Commons "Fake Prescription Pills". Drug Enforcement Administration (DEA). "Misuse of Prescription, Opioids, and Fake Pills". www.samhsa.gov. June 6, 2023.
=== Chemical industry === J. Peter Grace became CEO and president of Grace in 1945. Under the new leadership, the company began diversifying from the established shipping industry and Latin American operations that it had created. The company went from 60% of sales volume for Latin American operations in the 1950s to 19% of sale volume in 1962. In 1954, the company bought Davison Chemical Company (founded by William T. Davison) and the Dewey & Almy Chemical Company (founded in 1919 by Bradley Dewey and Charles Almy). Chemical sales growth went from 6% of sales in 1950 to 55% in 1977. When J. Peter Grace in 1978 was asked what may have been the best decision by the company, he stated the following:Well, I'd say buying Dewey & Almy. We paid $37 million when it was earning about $1.8 million, at about 20 times earnings. Today, its earning about $60 million.
Most Spanish Americans saw no reason to recognize a rump government that was under the threat of being captured by the French at any moment, and began to work for the creation of local juntas to preserve the region's independence from the French. Junta movements were successful in New Granada (Colombia), Venezuela, Chile and Río de la Plata (Argentina). Less successful, though serious movements, also occurred in Central America. Ultimately, Central America, along with most of New Spain, Quito (Ecuador), Peru, Upper Peru (Bolivia), the Caribbean and the Philippine Islands remained under control of royalists for the next decade and participated in the Cortes of Cádiz efforts to establish a liberal government for the Spanish monarchy.
Sources: en.wikipedia.org
==== Microbiological use ==== Acetylcysteine can be used in Petroff's method of liquefaction and decontamination of sputum, in preparation for recovery of mycobacterium. It also displays significant antiviral activity against influenza A viruses. Acetylcysteine has bactericidal properties and breaks down bacterial biofilms of clinically relevant pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Enterobacter cloacae, Staphylococcus epidermidis, and Klebsiella pneumoniae.
=== Efficacy of abrocitinib in treating atopic dermatitis === According to the latest meta-analysis in 2023, abrocitinib is both efficient and safe in treating moderate-to-severe AD in adolescents and adults. It also relieves itching rapidly and alleviates symptoms of AD. Abrocitinib gives significantly better results than the placebo at both 100 mg and 200 mg. The severity of AD is quantified through Eczema Area and Severity Index (EASI), which is based on the severity of lesion clinical signs. Abrocitinib was more effective than placebo in terms of EASI-reduction, but it also decreased other symptoms. The improvement of depression and anxiety was better in the experimental group than that in the control group. In another meta-analysis including 2256 patients from three different studies have shown that abrocitinib improved the EASI scores in comparison with dupilumab, even in the second week of treatment. A faster onset of Investigator's Global Assessment (IGA) response at the second week was also achieved by administering abrocitinib and early relief of itching occurred at 2 weeks. In other studies, abrocitinib (200 mg dose) achieved rapid relief from itching after four days of treatment compared with dupilumab and placebo in AD patients.
In 1997, the U.S. Department of Health and Human Services (HHS) appointed the Institute of Medicine (IOM) of the U.S. National Academy of Sciences (NAS) to investigate the potential risks of operative and post-operative complications from the emplacement of silicone breast implants. The IOM's review of the safety and efficacy of silicone gel-filled breast implants, reported that the "evidence suggests diseases or conditions, such as connective tissue diseases, cancer, neurological diseases, or other systemic complaints or conditions are no more common in women with breast implants, than in women without implants" subsequent studies and systemic review found no causal link between silicone breast implants and disease. In 1998, the U.S. FDA approved adjunct study protocols for silicone-gel filled implants only for breast reconstruction patients and for revision-surgery patients; and also approved the Dow Corning Corporation's Investigational Device Exemption (IDE) study for silicone-gel breast implants for a limited number of breast augmentation-, reconstruction-, and revision-surgery patients.
Because of its position at the mouth of the Guadalquivir, Sanlúcar is a convenient home base for exploring the nearby Doñana National Park (Parque Nacional de Doñana) and its natural features. Within the park lies the Marisma de Hinojos (Salt Marsh of Fennel Plants); also within its precincts is the possible site of the legendary lost city of Tartessos, the capital of an ancient civilization that predated the Phoenicians in Iberia.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.